The Effectiveness of Cervical Medial Branch Radiofrequency Ablation for Chronic Facet Joint Syndrome in Patients Selected by a Practical Medial Branch Block Paradigm
| Autor: | Richard Kendall, Aaron Conger, Zachary L McCormick, Russell Petersen, Masaru Teramoto, Shellie Cunningham, Taylor Burnham, Fabio Salazar |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Radiofrequency ablation Placebo Zygapophyseal Joint law.invention Rating scale law Internal medicine medicine Humans Neck pain Radiofrequency Ablation Neck Pain business.industry Medical record Nerve Block General Medicine Confidence interval Anesthesiology and Pain Medicine Cross-Sectional Studies Treatment Outcome Relative risk Neurology (clinical) medicine.symptom business Cohort study |
| Zdroj: | Pain medicine (Malden, Mass.). 21(10) |
| ISSN: | 1526-4637 |
| Popis: | Background Cervical medial branch radiofrequency ablation (CMBRFA) is an effective treatment for facetogenic pain in patients selected by Spine Intervention Society (SIS) guidelines of 100% symptom improvement with dual medial branch blocks (MBBs) ± placebo block. Patient selection for CMBRFA using ≥80% symptom improvement after dual concordant MBBs is common; however, this has not been studied. Objective To evaluate the effectiveness of CMBRFA and compare outcomes in individuals selected by 80–99% vs 100% symptom improvement with dual concordant MBBs. Design Cross-sectional cohort study. Methods Medical records of 87 consecutive patients were reviewed; 50 met inclusion criteria. A standardized telephone survey was performed at six or more months post-CMBRFA to query numerical rating scale (NRS) pain and patient global impression of change (PGIC) scores. The primary outcomes were the proportion of patients reporting ≥50% reduction of index pain. Results At a mean follow-up time of 16.9 ± 12.7 months, 54% (95% confidence interval [CI] = 35–73%) and 54% (95% CI = 32–74%) of the 80–99% and 100% MBBs groups, respectively, reported ≥50% pain reduction. Between-group comparison showed a relative risk of 0.99 (95% CI = 0.59–1.66) for meeting the primary outcome. Seventy percent (95% CI = 56–81%) of patients reported a PGIC score consistent with “improved or very much improved” at follow-up. Conclusions CMBRFA is an effective treatment in patients who report ≥80% symptom relief with dual concordant MBBs. The present study demonstrated an overall ≥50% pain reduction rate of 54% and no significant difference between those selected by 80–99% vs 100% symptom relief with dual concordant MBBs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|